Dysport becomes first toxin to be granted licence update for administration by healthcare professionals in the UK

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence update for Dysport in the treatment of focal spasticity. The update to the Summary of Product Characteristics (SmPC) means that any appropriately trained and qualified healthcare professionals, which now includes physiotherapists, will be able to administer the product to patients for the treatment of focal spasticity within its licensed indications. 

Dr Stephen Ashford, consultant physiotherapist at Northwick Park Hospital, London, said, “We are delighted by this news and it means the role of the physiotherapist in administration of botulinum toxin for spasticity management is recognised.”